You are now searching through our whole database. To make more specific queries, you can use our menu or go directly to papers, companies, trials, or events.
Plant Medicine Law Group is a pioneering law firm specializing in novel therapies within the mental health and wellness sectors. The firm is dedicated to supporting entrepreneurs in the psychedelic infrastructure space, offering a blend of large law firm quality with the personalized approach of a boutique practice.
This reanalysis of a single-blind neuroscience study (n=17) explores the relationship between brain structure and function, focusing on subjective experience through the use of psychedelic substances. It uses connectome harmonic decomposition to demonstrate that the connectome harmonic repertoire and entropy increase under DMT, and these measures correlate with the intensity of subjective experience, similar to effects seen with psilocybin, LSD, and ketamine.
This double-blind, pilot study (n=28) investigates esketamine combined with mindfulness-based intervention (MBI) for individuals with alcohol misuse problems. Esketamine enhanced psychological engagement in MBI and transiently decreased alcohol cravings, while also resulting in greater mystical experiences and dissociative states compared to placebo.
This review evaluates the role of music in psychedelic-assisted therapies (PAT) and indigenous entheogenic ceremonies. It examines neuroscientific, psychological, and anthropological research, highlighting the need for personalized music protocols and the integration of traditional practices into modern treatment models to enhance clinical outcomes.
This consensus statement (n=27) identifies key ethics and policy issues for integrating psychedelic therapies into clinical practice. It reports 20 points of consensus across 5 ethical issues, with relevant actors responsible for implementation, and highlights areas needing further research and deliberation.
This secondary analysis of a randomized, double-blind, crossover trial (n=61) evaluates the impact of ketamine on sleep metrics in individuals with treatment-resistant depression (TRD) compared to healthy volunteers (HVs). It finds that while ketamine affects delta and alpha power during sleep, it does not significantly alter sleep macroarchitecture or mediate its antidepressant and anti-suicidal effects through sleep variables.
This double-blind, placebo-controlled, full cross-over trial (n=30) will study the effects of psilocybin (10mg/70kg) on brain activity and thought dynamics in healthy volunteers.
Psilocybin versus ketamine – fast acting antidepressant strategies in treatment-resistant depression
This randomised, double-blind, controlled trial (n=60) will examine the rapid antidepressant effects of psilocybin (5mg) compared to ketamine (50mg) in patients with treatment-resistant depression (TRD).
This therapeutic exploratory Phase II trial (n=44) aims to assess the effects of low doses of psilocybin (5-10mg) on pain endurance and ratings of painfulness in fibromyalgia patients and healthy volunteers.
This randomised placebo-controlled parallel-group multi-centre trial (n=100; withdrawn) aimed to study the efficacy of ketamine infusion (35mg/70kg) in relieving symptoms of depression among patients who did not respond adequately to conventional treatment.
Psychedelic Database
Find everything on psychedelics as medicine. This page allows you to search through our whole database, from research papers to news articles, and from clinical trials to academic articles.
Next to our databases, don’t forget to check out our reports. The reports bring together the separate pieces of information from our database entries into written reports.
